NDT Advance Access originally published online on October 23, 2007
Nephrology Dialysis Transplantation 2008 23(1):369-373; doi:10.1093/ndt/gfm620
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ezetimibe treatment in hypercholesterolaemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study
1Department of Nephrology and Hypertension, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45122 Essen and 2Department of Nephrology, Klinikum rechts der Isar der Technischen Universität, Ismaninger Straße 22, 81675 München, Germany
Correspondence to: Oliver Witzke, Priv.-Doz. Dr med, Department of Nephrology & Hypertension, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, D-45122 Essen, Germany. Email: oliver.witzke{at}uk-essen.de
| Abstract |
|---|
Background. Ezetimibe has shown efficacy in the therapy of hypercholesterolemia in renal transplant patients. This is the first study investigating the effect of ezetimibe on renal function in kidney transplant recipients.
Methods. Fifty-six patients with statin-resistant hypercholesterolemia (total cholesterol >200 mg/dl) after renal transplantation received additional ezetimibe therapy (10 mg/day) for 12 months. A group receiving statin therapy (n = 28) served as controls in this prospective study.
Results. Total cholesterol and LDL cholesterol concentrations decreased significantly in the ezetimibe-treated patients but remained stable in the control group (delta total cholesterol: –24 ± 49 mg/dl vs 19 ± 49 mg/dl, P < 0.01; delta LDL: –30 ± 39 mg/dl vs – 3 ± 31 mg/dl, P < 0.01). Mean creatinine clearance remained stable in ezetimibe-treated patients but decreased significantly in control group (delta Cockcroft–Gault: 0.9 ± 7.3 ml/min vs – 4.8 ± 12.8 ml/min, P = 0.025; delta Modification of Diet in Renal Disease: –0.4 ± 6.2 ml/min/1.73 m2 vs 4.7 ± 8.8 ml/min/1.73 m2, P = 0.033).
Conclusions. The data of our prospective case–control study suggest that ezetimibe appears to ameliorate the decline of renal function after renal transplantation.
Keywords: allograft function; ezetimibe; hypercholesterolemia; renal transplantation
Received for publication: 27. 4.07
Accepted in revised form: 16. 8.07
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Sharma, M. T. Ansari, A. M. Abou-Setta, K. Soares-Weiser, T. C. Ooi, M. Sears, F. Yazdi, A. Tsertsvadze, and D. Moher Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia Ann Intern Med, November 3, 2009; 151(9): 622 - 630. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sharma, M. T. Ansari, A. M. Abou-Setta, K. Soares-Weiser, T. C. Ooi, M. Sears, F. Yazdi, A. Tsertsvadze, and D. Moher Systematic Review: Comparative Effectiveness and Harms of Combinations of Lipid-Modifying Agents and High-Dose Statin Monotherapy Ann Intern Med, August 31, 2009; (2009) 0000605-200911030-00144v1. [Abstract] [Full Text] |
||||
